Tratamiento con ocrelizumab en pacientes con esclerosis múltiple recurrente remitente en un centro cubano de atención terciaria: del análisis temporal al efecto global.
Saved in:
| Title: | Tratamiento con ocrelizumab en pacientes con esclerosis múltiple recurrente remitente en un centro cubano de atención terciaria: del análisis temporal al efecto global. |
|---|---|
| Alternate Title: | Ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis in a cuban tertiary care center: from temporal analysis to global effect. |
| Authors: | Leal, Irma Regla Olivera1 irolivera@infomed.sld.cu, Viera, Nelson Gómez1, García, Dania Ruiz1, Cue, Leda Fernández, Hernández, Darlis Yisel Carcases, Aguilar, Maria del Carmen1, Castellón, Roberto León1 |
| Source: | Revista Cubana de Neurología y Neurocirugía. 2025, Vol. 14, pe631-e652. 22p. |
| Subjects: | MULTIPLE sclerosis, THERAPEUTICS, HOSPITAL admission & discharge, DISEASE remission, DISEASE relapse, INTERFERON beta-1a, DISEASE progression |
| Geographic Terms: | CUBA |
| Abstract (English): | Introduction: Ocrelizumab has been used in patients with multiple sclerosis as a disease-modifying therapy. Studies have shown that it is beneficial in slowing relapses. Its use was introduced in Cuba, but no research had been conducted to determine the response to this therapy in our setting. Objective: to determine the impact of treatment with Ocrelizumab on relevant variables corresponding to patients with relapsing-remitting multiple sclerosis treated in a Cuban tertiary care center over four years, using a mixed approach of related measures and combined effect analysis. Methods: observational, descriptive, prospective study in patients of both sexes, 15 treated with ocrelizumab for one or more years, from march 2019 to march 2024 and a comparative group of 15 patients treated with rebif. The study variables were: disability measured with the EDSS scale, clinical and radiological relapses, annual hospital admission and NEDA. Results: Ocrelizumab significantly decreased radiological and clinical progression of the disease, as well as the number of hospital admissions, with a difference of no evidence of disease activity before and after ocrelizumab of 86.67% in the first year, 75.00% in the second year and 77.78% in the third year (p: 0.0002, P:0.0039 and p: 0.0156, respectively). In the forest plot analysis there is an effect in favor of Ovrelizumab in: reduction in the number of admissions, number of clinical flares, number of lesions in MRI and in no evidence of disease activity compared to Rebif. Conclusions: Treatment with ocrelizumab showed a favorable impact in: reduction in the number of admissions, number of clinical flares, radiological lesions in magnetic resonance imaging and no evidence of disease activity over the four years evaluated and in comparison, with the use of Rebif in patients with multiple sclerosis treated in a Cuban tertiary care center. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción: El ocrelizumab ha sido utilizado en pacientes con esclerosis múltiple como terapia modificadora de la enfermedad, los estudios realizados han mostrado beneficio para frenar las recaídas. En Cuba se introdujo su uso, pero no habían sido realizadas investigaciones que permitieran conocer la respuesta a esta terapéutica en nuestro medio. Objetivo: determinar el impacto del tratamiento con ocrelizumab en variables relevantes correspondientes a pacientes con esclerosis múltiple remitente recurrente atendidos en un centro cubano de atención terciaria a lo largo de cuatro años, aplicando un enfoque mixto de medidas relacionadas y análisis de efecto combinado. Métodos: estudio observacional, descriptivo, prospectivo en pacientes de ambos sexos, 15 tratados con ocrelizumab, por uno o mas años, desde marzo del 2019 a marzo 2024 y un grupo de 15 pacientes comparativo tratados con Rebif. Las variables de estudio fueron: la discapacidad medida con la escala de EDSS, recaídas clínicas y radiológicas, ingresos hospitalarios anuales y no evidencia de actividad de la enfermedad. Resultados: El ocrelizumab disminuyó significativamente la progresión radiológica y clínica de la enfermedad, así como el número de ingresos hospitalarios, observándose una diferencia de no evidencia de actividad de la enfermedad antes y despés de ocrelizumab de un 86,67 % al primer año, 75,00 % en el segundo y 77, 78 % al tercer año (p: 0.0002, P:0.0039 y p: 0.0156, respectivamente). En el análisis de los forest plot existe efecto a favor del ocrelizumab en: reducción del número de ingresos, número de brotes clínicos, número de lesiones en resonancia magnética y en no evidencia de actividad de la enfermedad en comparación con el Rebif. Conclusiones: El tratamiento con ocrelizumab mostró un impacto favorable en: reducción del número de ingresos, número de brotes clínicos, lesiones radiológicas en resonancia magnética y no evidencia de actividad de la enfermedad a lo largo de los cuatro años evaluados y en comparación con el uso de Rebif en pacientes con esclerosis multiple tratados en un centro cubano de atención terciaria. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Cubana de Neurología y Neurocirugía is the property of Sociedad Cubana de Neurologia y Neurocirugia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 192237642 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Tratamiento con ocrelizumab en pacientes con esclerosis múltiple recurrente remitente en un centro cubano de atención terciaria: del análisis temporal al efecto global. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis in a cuban tertiary care center: from temporal analysis to global effect. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Leal%2C+Irma+Regla+Olivera%22">Leal, Irma Regla Olivera</searchLink><relatesTo>1</relatesTo><i> irolivera@infomed.sld.cu</i><br /><searchLink fieldCode="AR" term="%22Viera%2C+Nelson+Gómez%22">Viera, Nelson Gómez</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22García%2C+Dania+Ruiz%22">García, Dania Ruiz</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Cue%2C+Leda+Fernández%22">Cue, Leda Fernández</searchLink><br /><searchLink fieldCode="AR" term="%22Hernández%2C+Darlis+Yisel+Carcases%22">Hernández, Darlis Yisel Carcases</searchLink><br /><searchLink fieldCode="AR" term="%22Aguilar%2C+Maria+del+Carmen%22">Aguilar, Maria del Carmen</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Castellón%2C+Roberto+León%22">Castellón, Roberto León</searchLink><relatesTo>1</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Cubana+de+Neurología+y+Neurocirugía%22">Revista Cubana de Neurología y Neurocirugía</searchLink>. 2025, Vol. 14, pe631-e652. 22p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22MULTIPLE+sclerosis%22">MULTIPLE sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22THERAPEUTICS%22">THERAPEUTICS</searchLink><br /><searchLink fieldCode="DE" term="%22HOSPITAL+admission+%26+discharge%22">HOSPITAL admission & discharge</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+remission%22">DISEASE remission</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+relapse%22">DISEASE relapse</searchLink><br /><searchLink fieldCode="DE" term="%22INTERFERON+beta-1a%22">INTERFERON beta-1a</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+progression%22">DISEASE progression</searchLink> – Name: SubjectGeographic Label: Geographic Terms Group: Su Data: <searchLink fieldCode="DE" term="%22CUBA%22">CUBA</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Introduction: Ocrelizumab has been used in patients with multiple sclerosis as a disease-modifying therapy. Studies have shown that it is beneficial in slowing relapses. Its use was introduced in Cuba, but no research had been conducted to determine the response to this therapy in our setting. Objective: to determine the impact of treatment with Ocrelizumab on relevant variables corresponding to patients with relapsing-remitting multiple sclerosis treated in a Cuban tertiary care center over four years, using a mixed approach of related measures and combined effect analysis. Methods: observational, descriptive, prospective study in patients of both sexes, 15 treated with ocrelizumab for one or more years, from march 2019 to march 2024 and a comparative group of 15 patients treated with rebif. The study variables were: disability measured with the EDSS scale, clinical and radiological relapses, annual hospital admission and NEDA. Results: Ocrelizumab significantly decreased radiological and clinical progression of the disease, as well as the number of hospital admissions, with a difference of no evidence of disease activity before and after ocrelizumab of 86.67% in the first year, 75.00% in the second year and 77.78% in the third year (p: 0.0002, P:0.0039 and p: 0.0156, respectively). In the forest plot analysis there is an effect in favor of Ovrelizumab in: reduction in the number of admissions, number of clinical flares, number of lesions in MRI and in no evidence of disease activity compared to Rebif. Conclusions: Treatment with ocrelizumab showed a favorable impact in: reduction in the number of admissions, number of clinical flares, radiological lesions in magnetic resonance imaging and no evidence of disease activity over the four years evaluated and in comparison, with the use of Rebif in patients with multiple sclerosis treated in a Cuban tertiary care center. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Introducción: El ocrelizumab ha sido utilizado en pacientes con esclerosis múltiple como terapia modificadora de la enfermedad, los estudios realizados han mostrado beneficio para frenar las recaídas. En Cuba se introdujo su uso, pero no habían sido realizadas investigaciones que permitieran conocer la respuesta a esta terapéutica en nuestro medio. Objetivo: determinar el impacto del tratamiento con ocrelizumab en variables relevantes correspondientes a pacientes con esclerosis múltiple remitente recurrente atendidos en un centro cubano de atención terciaria a lo largo de cuatro años, aplicando un enfoque mixto de medidas relacionadas y análisis de efecto combinado. Métodos: estudio observacional, descriptivo, prospectivo en pacientes de ambos sexos, 15 tratados con ocrelizumab, por uno o mas años, desde marzo del 2019 a marzo 2024 y un grupo de 15 pacientes comparativo tratados con Rebif. Las variables de estudio fueron: la discapacidad medida con la escala de EDSS, recaídas clínicas y radiológicas, ingresos hospitalarios anuales y no evidencia de actividad de la enfermedad. Resultados: El ocrelizumab disminuyó significativamente la progresión radiológica y clínica de la enfermedad, así como el número de ingresos hospitalarios, observándose una diferencia de no evidencia de actividad de la enfermedad antes y despés de ocrelizumab de un 86,67 % al primer año, 75,00 % en el segundo y 77, 78 % al tercer año (p: 0.0002, P:0.0039 y p: 0.0156, respectivamente). En el análisis de los forest plot existe efecto a favor del ocrelizumab en: reducción del número de ingresos, número de brotes clínicos, número de lesiones en resonancia magnética y en no evidencia de actividad de la enfermedad en comparación con el Rebif. Conclusiones: El tratamiento con ocrelizumab mostró un impacto favorable en: reducción del número de ingresos, número de brotes clínicos, lesiones radiológicas en resonancia magnética y no evidencia de actividad de la enfermedad a lo largo de los cuatro años evaluados y en comparación con el uso de Rebif en pacientes con esclerosis multiple tratados en un centro cubano de atención terciaria. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Cubana de Neurología y Neurocirugía is the property of Sociedad Cubana de Neurologia y Neurocirugia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=192237642 |
| RecordInfo | BibRecord: BibEntity: Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 22 StartPage: e631 Subjects: – SubjectFull: MULTIPLE sclerosis Type: general – SubjectFull: THERAPEUTICS Type: general – SubjectFull: HOSPITAL admission & discharge Type: general – SubjectFull: DISEASE remission Type: general – SubjectFull: DISEASE relapse Type: general – SubjectFull: INTERFERON beta-1a Type: general – SubjectFull: DISEASE progression Type: general – SubjectFull: CUBA Type: general Titles: – TitleFull: Tratamiento con ocrelizumab en pacientes con esclerosis múltiple recurrente remitente en un centro cubano de atención terciaria: del análisis temporal al efecto global. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Leal, Irma Regla Olivera – PersonEntity: Name: NameFull: Viera, Nelson Gómez – PersonEntity: Name: NameFull: García, Dania Ruiz – PersonEntity: Name: NameFull: Cue, Leda Fernández – PersonEntity: Name: NameFull: Hernández, Darlis Yisel Carcases – PersonEntity: Name: NameFull: Aguilar, Maria del Carmen – PersonEntity: Name: NameFull: Castellón, Roberto León IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 22254676 Numbering: – Type: volume Value: 14 Titles: – TitleFull: Revista Cubana de Neurología y Neurocirugía Type: main |
| ResultId | 1 |
